March 3, 2026Open Access

Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function

Key Points

PCSK9 inhibition reduces lipoprotein-associated phospholipase A2 levels, indicating decreased inflammation.
Inflammatory marker IP-10 also decreases without affecting global inflammatory response or HDL antioxidant function.
Assessment of the treatment shows that it targets chronic vascular inflammation effectively.
Findings highlight the possibility of managing cardiovascular risks without altering the immune system dramatically.

Abstract

PCSK9 inhibition reduces LpPLA2 and IP-10 without changing global inflammatory response or antioxidant function of HDL, which might indicate a decrease in chronic vascular inflammation without an undesired broad systemic immune alteration.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Seidel et al. (Sun,) studied this question.

synapsesocial.com/papers/69a759e1c6e9836116a1f452 https://doi.org/https://doi.org/10.1016/j.jacl.2026.02.003

Bookmark

View Full Paper